New Delhi: Since Covid cases in the middle of low vaccine reserves are growing in India, the center has established a committee to review the situation and ensure that the country is ready to control the developed situation.
The panel, established by the Ministry of Health Care and Family Care, met at the beginning of this week and last week to discuss COVID readiness, including low vaccine, supervision, testing, beds and drugs, said two people who acquainted and talked about the state of anonymity.
The best scientists and officials of the Committee of the National Committee called on the supervision of the strong, increased the pace of testing and issued advice, said these two people. The panel also reviewed the COVID-19 vaccines with regard to the vulnerable and high-risk population, including older or people with co-morbid conditions, and recommended to expand the number of beds and drugs in hospitals, the official said.
The meeting was attended by officials of the General Directorate for Health Services (DGHS), the National Disease Control Center (NCDC) and Indian Council of Medical Research (ICMR).
Questions E -mail E -Mail the Minister of Health of the JP of the Nadd’s Office, Minister of Health Punya Salil Srivastava and spokesperson of the Ministry of Health 28. May remained unanswered until the press.
The Ministry of Biotechnology (DBT) and other government laboratories perform environmental supervision, collect and analyze waste water samples to understand the latest increase in Covid-19. Delhi, Bombai, Pune, Kolkata, Ahmedabad, Bengaluru and Thiruvananthapuram see an increase in new patients with Covid. India announced 1,010 active Covid cases by May 26, with seven people succumbing to an infection. However, the Ministry of Health must officially confirm the mortality figures.
The country has already launched the genomic sequencing of COVID-19 cases to identify a variant for a recent increase, writing the genome by the National Institute of Virology (NIV-Pune). Two new variants of Koronavir – nb.1.8.1 and LF.7 – in India mutated from the earlier variant Jn.1.
Mild variant
The Indian Institute in Serum and Bharat Biotech produced billions of Indian vaccines and more than 100 countries during the first few wave of pandemic. After the situation relaxed, the last doses of the Covid vaccine were produced a year ago without seeing new supplies.
“Right now, the virus looks very slightly. We are monitoring the number of Covid-19-19 cases and hospitalizations that take place across the country, and have warned all laboratories,” said the second government official. “We discussed the COVID-19-19-19th and other supervision strategies.”
Medical research shows that vaccines provide two different levels of protection. The first is against infection, which is short -term and naturally deals with about six months. In addition, the virus is also constantly changing. The second type of protection is long -term and protects our internal organs from serious diseases.
A government scientist, when he talked about the state of anonymity, said that almost all individuals had closed Covid-19 infection several times.
“People have developed a hybrid immunity (natural plus immunity through a vaccine). In this situation, the requirement for the power of the booster is very negligible. This infection is now very mild, and therefore the vaccine may not be needed,” the scientist said. “Previously, there was also no strong recommendation for the strengthening dose. Hospitalization is primarily caused by co -morbid or basic health conditions. Vaccines also do not prevent any infection.”
Public health experts said there was no reason to panic, because the cases were mild, and at the same time recommend the development of vaccines for the latest option.
“There are several reports on hospitalization and deaths, but these deaths are reported in patients with co -morbidities. The government of Tamil also said that the death that occurred was a co -ownership finding Covida because we increased our test capacity,” Dr. Tymya Swaminathan, a former director of the Indian Council on Medical Research (ICMR) and a former main scientist who was on the basis of our main scientist.
ICMR supervision data suggest that there is no excessive increase in the severity of hospitals or death and vaccine, however, will not prevent mild infections, Dr. Swaminathan and, despite vaccination, quoted omicron wool. “The immunity we have now protects us, so we get mild infections,” she said. “Perhaps in the future the COVID variant is changing to another serious mutant, then we have to quickly adjust and produce these vaccines and then have a program. Even in the current scenario, the strengtheners do not seem to be needed.”
New variant vaccine
Dr. Swaminathan suggested that companies have to create a vaccine using the latest variant that can now be done. “When we get the genome sequencing data, companies should be able to create this vaccine. It makes no sense to provide an old vaccine made from the original Covida tribe,” she said, adding many companies in the West to update her vaccines every year.
WHO did not classify a new Covid mutation as a “variant of concern or a variant of interest” and advised older and high -risk people to be careful and masks when they go out.
The Covid vaccination approach varied with each country on the basis of the burden of the disease, said Dr. Rajeev Jayadevan, the previous President of the Indian Medical Association (IMA), Cochin Dr Rajeev Jayadevan, who quoted a conservative approach of Scandinavian nations and aggressive vaccination.
“The Indian population is already well immunized. Our percentage of vaccination coverage is also high, with limited hesitation of the vaccine. We are probably preferred to supply vaccines to those who were significantly greater risk of death and serious illness,” he said. “In the following years, the population was also exposed to various versions of this virus. This deleted the lack of immune memory, which contributed to death and severe illness in the early part of the pandemic.”
“The disease has now become milder, which changes the balance of decision -making,” Dr. Jayadevan. “While strategies of mitigation are important to reduce spread, there is no role for the shots of the universal strengthening vaccine.”
(Tagstotranslate) Covid
